80 related articles for article (PubMed ID: 3480697)
21. [Studies on multiple mucosal biopsy in patients with bladder cancer. 4. Evaluation of Thomsen-Friedenreich antigen in multiple mucosal biopsy and transitional cell carcinoma of the bladder].
Igawa M
Hinyokika Kiyo; 1986 Nov; 32(11):1663-76. PubMed ID: 3825815
[TBL] [Abstract][Full Text] [Related]
22. Expression of carbohydrate antigens (SSEA-1, sialyl-Lewis X, DU-PAN-2 and CA19-9) and E-selectin in urothelial carcinoma of the renal pelvis, ureter, and urinary bladder.
Kajiwara H; Yasuda M; Kumaki N; Shibayama T; Osamura Y
Tokai J Exp Clin Med; 2005 Sep; 30(3):177-82. PubMed ID: 16285609
[TBL] [Abstract][Full Text] [Related]
23. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
[TBL] [Abstract][Full Text] [Related]
24. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.
Genega EM; Hutchinson B; Reuter VE; Gaudin PB
Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of urine ferritin determination in urologic malignancies.
Tang DJ; Fan XY; Huang XB; Chen PH; Liang Y; Lang YM
Chin Med J (Engl); 1989 May; 102(5):356-60. PubMed ID: 2509157
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2].
Ohkura H; Sakawaki T
Gan No Rinsho; 1985 May; 31(6 Suppl):583-8. PubMed ID: 3861882
[TBL] [Abstract][Full Text] [Related]
27. Tumor antigen TA-4: an aid in detecting post-operative recurrences of esophageal carcinoma.
Sugimachi K; Kitamura M; Matsuda H; Okudaira Y
Dis Markers; 1987 Jun; 5(2):67-73. PubMed ID: 3502985
[TBL] [Abstract][Full Text] [Related]
28. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment.
Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M
Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the prognostic significance of cytosolic determination of CA 125 tumor-associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with nonsmall cell lung carcinoma.
Picardo AL; Diez M; Torres A; Maestro M; Ortega D; Hernando F; Gómez A; Garcia-Asenjo J; Balibrea JL
Cancer; 1996 Mar; 77(6):1066-72. PubMed ID: 8635125
[TBL] [Abstract][Full Text] [Related]
30. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
[TBL] [Abstract][Full Text] [Related]
31. [Quantification of bladder tumor antigen (BTA trak) and its correlation with bladder cancer grade and stage].
Rodríguez Martínez JJ; Escaf Barmadah S; Allende MT; Raigoso P; Martín Benito JL; Pérez García FJ; Fernández Gómez JM
Arch Esp Urol; 2000; 53(1):1-6. PubMed ID: 10730418
[TBL] [Abstract][Full Text] [Related]
32. Primary seminal vesicle carcinoma: an immunohistochemical analysis of four cases.
Ormsby AH; Haskell R; Jones D; Goldblum JR
Mod Pathol; 2000 Jan; 13(1):46-51. PubMed ID: 10658909
[TBL] [Abstract][Full Text] [Related]
33. Monocyte tissue factor levels in cancer patients.
Lwaleed BA; Francis JL; Chisholm M
Saudi Med J; 2000 Aug; 21(8):722-9. PubMed ID: 11423883
[TBL] [Abstract][Full Text] [Related]
34. Bladder tumor antigen stat test in non-urothelial malignant urologic conditions.
Wald M; Halachmi S; Amiel G; Madjar S; Mullerad M; Miselevitz I; Moskovitz B; Nativ O
Isr Med Assoc J; 2002 Mar; 4(3):174-5. PubMed ID: 11908255
[TBL] [Abstract][Full Text] [Related]
35. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB
Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562
[TBL] [Abstract][Full Text] [Related]
36. [Study on the tumor immunity of renal cell carcinoma--with special reference to the significance of leukocyte adherence inhibition test].
Okada Y
Hinyokika Kiyo; 1984 Oct; 30(10):1367-77. PubMed ID: 6395679
[TBL] [Abstract][Full Text] [Related]
37. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical localization of prostate carcinoma-associated antigens.
Wright GL; Beckett ML; Starling JJ; Schellhammer PF; Sieg SM; Ladaga LE; Poleskic S
Cancer Res; 1983 Nov; 43(11):5509-16. PubMed ID: 6193873
[TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
40. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
